Protein A Affinity Capture followed by AdvanceBio SEC Aggregation Analysis using the Agilent Infinity Series 2D-LC System

Significance of the Topic

Protein biopharmaceuticals such as monoclonal antibodies and recombinant proteins exhibit complex structures and functions that are vital for treating diseases like cancer and autoimmune disorders. Accurate characterization of protein aggregates is essential for ensuring drug safety, efficacy, and regulatory compliance.

Study Objectives and Overview

This study demonstrates a two-dimensional liquid chromatography (2D-LC) workflow combining Protein A affinity capture with size exclusion chromatography (SEC) to analyze monoclonal antibody aggregation in a single injection. The goal is to streamline aggregate quantification by eliminating manual fraction collection and reducing analysis time.

Methodology and Instrumentation Used

The 2D-LC system comprised an Agilent 1260 BioLC for the first dimension and an Agilent 1290 binary pump for the second dimension, linked via a quick-change 2D valve and a multiple heart-cutting valve with pre-installed loops. Key components and conditions included:

• First Dimension: Agilent Bio-Monolith Protein A column at room temperature, 0.75 mL/min flow, mobile phases of 100 mM PBS (capture) and 500 mM acetic acid (elution).
• Heart-cutting interface: Twelve 40 µL loops to trap eluate fractions.
• Second Dimension: Agilent AdvanceBio SEC 300 Å column (2.7 µm, 25 °C), isocratic 10 mM PBS pH 7.4 at 0.35 mL/min with diode array detection.

Key Results and Discussion

The integrated 2D method successfully captured monoclonal antibodies via Protein A affinity and immediately resolved monomer, dimer, and higher-order aggregates by SEC. Single-injection workflows eliminated sample handling and fraction collection. Heat-stressed IgG samples (65 °C, 24 h) exhibited increased aggregate peaks, clearly separated from monomer species, confirming the method’s sensitivity and resolution.

Benefits and Practical Applications of the Method

The combined workflow offers:

• Efficient determination of antibody titer and aggregate content in one analysis.
• Reduction of manual steps and risk of sample contamination.
• Improved throughput for process development and quality control laboratories.
• Accurate quantification of aggregates thanks to high resolution SEC in the second dimension.

Future Trends and Potential Applications

Advances may include further miniaturization and automation of 2D-LC platforms, new affinity ligands for diverse biotherapeutics, direct coupling with mass spectrometry for structural analysis, and real-time aggregate monitoring during upstream bioprocessing.

Conclusion

The Agilent Infinity Series 2D-LC approach combining Protein A capture with AdvanceBio SEC enables rapid, accurate aggregation analysis of monoclonal antibodies in a single injection. This streamlined workflow enhances laboratory efficiency, reduces manual handling, and delivers high-quality data for biopharmaceutical development and QC.

Reference

• Analysis of Monoclonal Antibody Digests with the Agilent 1290 Infinity 2D-LC Solution, Agilent Technologies Application Note 5991-2880EN, 2013.
• Rapid Human Polyclonal IgG Quantification Using the Agilent Bio-Monolith Protein A HPLC Column, Agilent Technologies Application Note 5989-9733EN, 2008.
• Agilent Bio-Monolith Protein A Monitors Monoclonal Antibody Titer from Cell Cultures, Agilent Technologies Application Note 5991-2990EN, 2014.